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ABSTRACT 
The glutamate system is implicated in the pathophysiology of schizophrenia and mood disorders. 
Using functional magnetic resonance spectroscopy (1H-fMRS), it is possible to monitor glutamate 
dynamically in activated brain areas and may give a closer estimate of glutamatergic 
neurotransmission than standard magnetic resonance spectroscopy. 14 patients with schizophrenia, 
15 patients with bipolar disorder II (BPII) and 14 healthy volunteers underwent a 15-min N-back task 
in a 48s block design during 1H-fMRS acquisition. Data from the first, second and third 16s group of 8 
spectra for each block were analysed to measure levels of glutamate and Glx (glutamate + 
glutamine), scaled to total creatine (TCr), across averaged 0-back and 2-back conditions. A 6x3 
repeated-measures analysis of variance (rmANOVA) demonstrated a significant main effect of time 
for Glx/TCr (P=0.022). There was a significant increase in Glu/TCr (P=0.004) and Glx/TCr (P<0.001) 
between the final spectra of the 0-back and first spectra of the 2-back condition in the healthy 
control group only. 2x2 rmANOVA revealed a significant time by group interaction for Glx/TCr 
(P=0.019) across the 0-back condition, with levels reducing in healthy controls and increasing in the 
schizophrenia group. While healthy volunteers showed significant increases in glutamatergic 
measures between task conditions, the lack of such a response in patients with schizophrenia and 
BPII may reflect deficits in glutamatergic neurotransmission. Abnormal increases during periods of 
relatively low executive load, without the same dynamic modulation as healthy volunteers with 
increasing task difficulty, further suggests underlying abnormalities of glutamatergic 
neurotransmission in schizophrenia. 
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1. INTRODUCTION 
There has been considerable interest in the role of glutamatergic neurotransmission in the 
pathophysiology of schizophrenia (Moghaddam and Javitt, 2012). It is proposed N-methyl-D-
aspartate receptor (NMDAR) hypofunction leads to excess cortical glutamate release 
(Lisman et al., 2008; Olney et al., 1999) with downstream effects on dopamine and other 
neurotransmitter systems (Howes et al., 2015; Stone et al., 2007). Determining the nature 
of glutamatergic abnormalities in schizophrenia may prove useful in understanding 
symptomatology and further developing novel treatment strategies (Stone, 2011). 
Glutamatergic abnormalities are not specific to schizophrenia however, and there has been 
particular interest in this system with respect to the pathophysiology (Sanacora et al., 2012) 
and treatment of mood disorders (Zarate et al., 2010). 
Proton magnetic resonance spectroscopy (1H-MRS) has been central to the investigation of 
glutamatergic dysfunction in schizophrenia, revealing abnormal levels of glutamate and its 
metabolite glutamine across various cortical and subcortical brain regions in patients 
compared with controls (Marsman et al., 2013; Merritt et al., 2016). Alterations in medial 
prefrontal glutamate levels have also been reported in mood disorders with reduced levels 
generally reported in major depressive disorder (MDD) (Yuksel and Ongur, 2010). In patients 
with bipolar affective disorder, it has been suggested that medial prefrontal glutamate 
levels may be elevated, although this finding has not been consistently seen (Jun et al., 
2014; Taylor, 2014; Yuksel and Ongur, 2010). 
A significant limitation of 1H-MRS studies is that measurements are determined over a single 
static time period. Functional 1H-MRS (1H-fMRS) is a technique where a series of MRS 
acquisitions are acquired upon functional brain activation. It is being increasingly applied to 
investigate dynamic changes in brain metabolites (Duarte et al., 2012) and may give a closer 
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estimate of glutamatergic neurotransmission than standard magnetic resonance 
spectroscopy (Jelen et al., 2018; Mullins, 2018) . 
1H-fMRS studies have demonstrated increases in glutamatergic measures in the occipital 
cortex following visual stimulation (Bednarik et al., 2015; Ip et al., 2017; Lin et al., 2012; 
Mangia et al., 2007; Prichard et al., 1991; Schaller et al., 2013), the motor cortex using a 
finger-tapping (Schaller et al., 2014) and hand-clenching paradigm (Chen et al., 2017), and 
the anterior cingulate cortex (ACC) using painful stimuli (Cleve et al., 2015; Mullins et al., 
2005) in healthy controls. This technique has been further applied in healthy controls to 
demonstrate increases in  glutamate in the dorsolateral prefrontal cortex (dlPFC), during a 
working memory task (Woodcock et al., 2018), and the ACC using the Stroop Task as a 
cognitive paradigm (Kuhn et al., 2016; Taylor et al., 2015b). Taylor et al. (2015a) undertook a 
subsequent 1H-fMRS study of the ACC using the Stroop task in patients with schizophrenia 
and MDD compared with healthy volunteers. While the healthy control group again showed 
significant increases in glutamate concentrations during the Stroop Task, this was not seen 
in the schizophrenia or MDD group. 
The purpose of this study was to examine dynamic glutamatergic levels in the ACC during 
performance of the N-back task in patients with schizophrenia and bipolar II disorder (BPII), 
compared with healthy controls, using 1H-fMRS at 3-Tesla. The N-back task is a working 
memory task with variable levels of complexity, allowing the investigation of different 
degrees of cognitive load and has been shown to robustly activate the ACC, dysfunction of 
which is consistently implicated in schizophrenia (Adams and David, 2007) and bipolar 
disorder (Maletic and Raison, 2014). It was hypothesized that there would be increases in 
glutamatergic measures in the more cognitively demanding 2-back condition compared with 
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the 0-back condition but that the schizophrenia group would show smaller increases than 
the healthy control and BPII groups. 
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2. EXPERIMENTAL PROCEDURES 
Participants 
This study was reviewed and approved by the London Harrow Research Ethics Committee 
and all participants provided written informed consent.15 participants with a diagnosis of 
schizophrenia were recruited through the Psychosis Clinical Academic Group, South London 
and Maudsley NHS Foundation Trust together with 15 BPII participants from the Improving 
Access to Psychological Therapies services. 14 healthy controls were recruited from local 
and online advertisements. 
All participants were right handed and aged between 22 and 57 years old. Volunteers with 
major medical illnesses, other psychiatric disorders, magnetic resonance imaging (MRI) 
contraindications or current substance abuse were excluded from the study. Healthy 
volunteers with a family history of psychiatric disorder in a first degree relative were also 
excluded. 
Diagnosis was established by a psychiatrist and trained research assistant with the Mini 
International Neuropsychiatric Interview (MINI) (Sheehan et al., 1998). All participants were 
assessed with the Scale for the Assessment of Positive/Negative Symptoms (SAPS/SANS) 
(Andreasen, 1984a, b), Montgomery-Asberg Depression Rating Scale (MADRS) (Montgomery 
and Asberg, 1979) and Young Mania Rating Scale (YMRS) (Young et al., 1978). Thirteen 
schizophrenia patients were receiving regular antipsychotic medication (four taking 
olanzapine; three taking risperidone; two taking aripiprazole; three taking clozapine; one 
taking haloperidol) and two were not currently medicated. Five BPII patients were receiving 
antidepressants (three taking citalopram; one taking sertraline; one taking fluoxetine) and 
the remaining ten were not taking psychotropic medication. The healthy controls were 
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medication-naïve. Demographic information including age, sex and clinical rating scores are 
shown in Table 1. 
N-back task paradigm 
Participants performed the N-back task for 15-min while 1H-fMRS spectra were acquired 
(Figure 1). This consisted of 18 blocks lasting 48s each, rotating through alternating 
conditions (0-back, 1-back, 2-back, 3-back i.e., n= 0, 1, 2 or 3). As sequential letters were 
presented individually, subjects were asked to respond “Yes” as quickly and accurately as 
possible on a two-button keypad, each time a new letter was presented that was the same 
as one presented “n” items before. For the 0-back condition this involved correctly 
identifying the letter “X” whenever it was displayed. Both accuracy and response times were 
recorded for analysis. 
1H-fMRS data acquisition and analysis 
All measurements were acquired on a GE Discovery MR750 3.0T scanner with a body-
transmit coil and 12-channel Head/Neck/Spine receiver coil. 1H-fMRS voxels were 3×2×2cm 
(12cm3) in size. In each participant the voxel was not rotated, but was aligned with its 
inferior edge on the superior surface of the corpus callosum, with its centre positioned 7mm 
posterior to the genu of the corpus callosum in the sagittal plane and in the midline of the 
brain, as defined by the interhemispheric fissure in the transverse plane (Figure 2), using a 
high resolution structural 3D MP-RAGE sequence (TR = 7312ms, TE = 3016ms, TI =400ms, FOV 
= 270mm, flip-angle (a) = 11°, matrix size = 256×256mm2, slice thickness = 1.2mm, 196 
slices) in the sagittal plane for localization of the spectroscopy. 
1H-fMRS spectra were acquired individually throughout the N-back task using Point 
RESolved Spectroscopy (PRESS), with CHEmical Selective suppression for water suppression 
and outer volume suppression (OVS) with Very Selective Suppression (VSS) pulses (TR = 
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2000ms, TE = 105ms, NEX= 8). A modified version of GE’s PROBE (proton brain examination) 
sequence was used to commence the N-back task and send a trigger pulse at the start of 
every TR. Shimming was optimized with an auto-prescan performed twice before each scan. 
For each participant 16 water-unsuppressed and 432 water-suppressed spectra were 
collected; 3 spectra (each an average of an eight-step phase cycle) acquired every 48s 
during each of the 18 blocks of N-back task.  
Spectral analysis was performed using the TARQUIN software package, version 4.3.6 (Wilson 
et al., 2011). The TARQUIN algorithm performed a fully automated fit to the data using a 
predefined basis set comprising of the following components: alanine; aspartate; creatine 
(Cr); gamma-aminobutyric acid; glucose; glutamine; glutathione; glutamate (Glu); 
glycerophosphorylcholine; myo-inositol; lactate; lipid peaks at 0.9, 1.3a, 1.3b, and 2.0 ppm; 
macromolecules at 0.9, 1.2, 1.4, and 2.0 ppm; N-acetyl-aspartate (NAA); N-acetyl-
aspartateglutamate ; phosphorylcholine; phosphocreatine (PCr); scyllo-inositol; and taurine.  
Spectra acquired from the 0-back and 2-back task conditions (8 blocks of each) were 
averaged together and measures of Glu and Glx (Glu+ glutamine), scaled to total creatine 
(TCr - Cr + PCr), were recorded allowing the mean differences in concentrations between 
task conditions to be calculated. Additionally, averaged measures of the first, second and 
third spectra from each of the cumulative 0-back and 2-back conditions were recorded to 
investigate metabolite level changes across blocks. The 1-back and 3-back conditions (1 
block each) were not analysed as these were included purely as a distractor between the 0-
back and 2-back conditions.  
Several 1H-fMRS studies have reported line width reductions in spectral measures as might 
be expected due to a decrease in local field homogeneity that accompanies the BOLD effect 
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(Bednarik et al., 2015; Mangia et al., 2007). This effect can be addressed by referencing to 
another peak that may have experienced the same effect (Lally et al., 2014), which was 
achieved through the use of TCr scaling in this study. We excluded any metabolite measures 
with a Cramer-Rao minimum variance bounds (CRMVB) of greater than 20%, a signal-to-
noise ratio (SNR) >5, a full-width half-maximum (FWHM) of <0.50 ppm or fit quality (Q) of 
<2.5. One participant in the schizophrenia group had a gold tooth causing interference and 
poor spectral quality so was excluded from all analyses. 
To explore relative 1H-fMRS voxel tissue composition, the structural images were 
segmented into grey matter, white matter and cerebrospinal fluid (CSF) using Statistical 
Parametric Mapping 8 (SPM8; Wellcome Department of Imaging Neurosciences, University 
College London, United Kingdom) with the coordinates of each voxel were mapped onto the 
segmented structural image using in-house software. 
Statistics 
All statistical analyses were performed with SPSS version 22.0 (SPSS, Chicago, Illinois) using 
two-tailed tests. Shapiro-Wilk tests were used to ensure assumptions of normality. A priori 
hypotheses were evaluated using paired t-tests to compare mean metabolite changes for 
the three groups, together with all participants combined, between the total averaged 0-
back and 2-back task conditions. To accommodate for multiple comparisons, a Bonferroni-
correction was applied (alpha=0.05/4). A 6x3 repeated-measures analysis of variance design 
(rmANOVA) (alpha=0.05) using glutamatergic measures across the first, second and third 
spectra from each of the cumulative 0-back and 2-back conditions was used to determine 
significant variations over time and across the three groups. 
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In addition, several post-hoc analyses were performed. Bonferroni-corrected pairwise 
comparisons of glutamatergic measures between each time point were used to determine 
between which time points any significant changes occurred in the rmANOVA. Further 
paired t-tests were used to compare mean metabolite changes for each group between 
those time points where such significant changes occurred (alpha=0.05/4). An exploratory 
2x2 rmANOVA was performed (alpha=0.05), comparing glutamatergic measures at the 
beginning and end of the 0-back condition in the healthy control versus schizophrenia 
group. To confirm any changes detected in glutamate or Glx corrected for TCr, separate 
analyses were carried out using correction for total N-acetylaspartate (TNAA). Finally, 
Pearson correlation coefficients were used to examine any relationship between changes in 
Glu/TCr or Glx/TCr levels between 0-back and 2-back conditions and 1) age, 2) change in 
response accuracy, 3) change in response times and 4) clinical rating scores for each group 
(uncorrected, alpha=0.05). 
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3. RESULTS 
Metabolite Level Differences 
Concentrations of Glu/TCr and Glx/TCr in the total averaged 0-back and 2-back conditions 
were not found to be significantly different in any of the separate or combined groups 
(Table 2). The 6x3 rmANOVA (alpha=0.05) yielded a significant main effect of time for 
Glx/TCr (P=0.022) but not for Glu/TCr (P=0.673). There were no significant time by group 
interactions for Glu/TCr (P=0.296) or Glx/TCr (P=0.610) and no significant main effects of 
group for either Glu/TCr (P=0.689) or Glx/TCr (P=0.919). Post-hoc tests using the Bonferroni 
correction revealed Glx/TCr levels significantly increased (P=0.038) between the end of the 
0-back condition (averaged third spectra of 0-back) and the beginning of the 2-back 
condition (averaged first spectra of 2-back). Further analyses revealed a significant increase 
in both Glu/TCr (P=0.004) and Glx/TCr (P<0.001) in the healthy control group between these 
two time points. The individual schizophrenia and BPII groups did not show any significant 
changes in Glu/TCr or Glx/TCr for this comparison. Averaged time courses of Glx/TCr levels 
for the first, second and third spectra across the 0-back and 2-back conditions are shown in 
Figure 3, according to participant group. 
Across the 0-back condition healthy control and BPII groups showed a general reduction in 
Glx/TCr while patients with schizophrenia showed an increase in both (Figure 4). 
Exploratory analyses with 2x2 rmANOVA (alpha=0.05) yielded a significant time by group 
interaction (P=0.019) for Glx/TCr across the 0-back condition in healthy control versus 
schizophrenia group, with no significant main effects of time (P=0.616) or group (P=0.832).  
The post-hoc analyses using correction with TNAA mirrored the main findings obtained for 
correction with TCr. 6x3 rmANOVA revealed a significant main effect of time for Glx/TNAA 
(P=0.039) but not Glu/TNAA (P=0.413). Concentrations of Glu/TNAA and Glx/TNAA in the 
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total averaged 0-back and 2-back conditions were not significantly different in any of the 
separate or combined groups. For all groups combined there was a significant increase in 
Glx/TNAA (P=0.008), but not Glu/TNAA (P=0.105), between the averaged third spectra of 0-
back and averaged first spectra of 2-back.  A significant increase in Glu/TNAA (P=0.005) and 
Glx/TNAA (P=0.006), was seen between these two time points in the healthy control group 
but not in the individual schizophrenia and BPII groups. 
Tissue Segmentation 
The mean 1H-fMRS voxel tissue composition proportions are shown in Table 3 according to 
participant group. There was a significant difference in grey matter proportion between 
groups as determined by one-way ANOVA (F(2,40)= 5.488, P=0.008). The schizophrenia 
groups had a significantly lower mean grey matter proportion compared with the healthy 
control group (P=0.006) but not the BPII group. There was no significant difference in grey 
matter proportion between the healthy control and BPII groups. In terms of CSF and white 
matter proportions there were no significant differences between the groups. 
Task Performance 
The mean accuracy and response times for the 0-back and 2-back conditions are shown in 
Table 4. In terms of accuracy, there was a significant difference between groups as 
determined by one-way ANOVA for the 0-back (F(2,40)= 8.313, P<0.001) and 2-back 
conditions (F(2,40)= 7.897, P=0.001). The schizophrenia group had significantly lower mean 
response accuracy for the 0-back condition compared with the healthy control (P=0.006) 
and BPII groups (P=0.002). There was no significant difference in accuracy for the 0-back 
condition between the healthy control and BPII groups. Likewise, for the 2-back condition, 
the schizophrenia group had significantly lower response accuracy compared with the 
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healthy control (P=0.003) and BPII groups (P=0.007), but there was no statistically significant 
difference between the healthy control and BPII groups.  
For the response times, there was a significant difference between groups for the 0-back 
(F(2,40)= 6.364, P=0.004) and 2-back conditions (F(2,40)= 3.764 P=0.032). The schizophrenia 
group took significantly longer to respond in the 0-back condition compared with the 
healthy control (P=0.012) and BPII groups (P=0.010), with no significant difference between 
the healthy control and BPII groups. In the 2-back condition the schizophrenia group again 
took significantly longer to respond compared with healthy control group (P=0.049) but this 
did not reach significance when compared with the BPII group. There was no significant 
difference between healthy control and BPII group for response times in the 2-back 
condition.  
Correlation Analyses 
Results from exploratory analyses examining bivariate correlations are shown in Tables 5 
and 6. In terms of correlations with metabolite level changes between total averaged 0-back 
and 2-back conditions there was a significant moderate negative correlation between 
change in Glx/TCr and change in accuracy seen in the schizophrenia group and a significant 
weak positive correlation between change in Glx/TCr and change in response time for all 
groups combined. 
For correlations with metabolite level changes, specifically between averaged third spectra 
of 0-back and averaged first spectra of 2-back, there was a significant strong negative 
correlation between change in Glu/TCr and change in response time in the healthy control 
group. In the BPII group there was a strong positive correlation between change in Glu/TCr 
and change in accuracy together with negative correlations between changes in Glu/TCr and 
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Glx/TCr, and MADRS score. Across groups there were highly significant negative correlations 
between changes in Glu/TCr and Glx/TCr, and MADRS score. For all groups combined there 
were also significant negative correlations between change in Glu/TCr and SAPS/SANS 
scores. 
There were no significant correlations between age and any of the metabolite level change 
comparisons between 0-back and 2-back conditions in any of the separate or combined 
groups.  
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4. DISCUSSION 
A main effect of time for Glx/TCr was observed across the 0-back and 2-back conditions for 
all the groups. Although there were not any significant differences in Glu/TCr and Glx/TCr 
between total averaged 0-back and 2-back conditions in any of the groups, a significant 
increase in Glx/TCr was seen between the end of the 0-back condition and beginning of 2-
back condition for all groups combined. The healthy control group specifically showed a 
significant increase in both Glu/TCr and Glx/TCr for this comparison, while the schizophrenia 
group showed no significant changes. Although the BPII group did not show significant 
changes for this comparison either, the averaged time-course pattern was closer to that of 
healthy controls and the lack of significance may be the result of insufficient power. 
The absence of any significant changes in Glu/TCr or Glx/TCr in the schizophrenia group 
between the 0-back and 2-back conditions supports our hypothesis of an impaired 
glutamatergic response and is comparable to findings by Taylor et al. (2015a), where 
although increased glutamate levels were detected in the dorsal ACC during a Stroop task in 
healthy controls, no significant change in glutamate was observed in individuals with 
schizophrenia. These findings are supported by functional MRI studies that have 
demonstrated ACC deficits in schizophrenia in studies of executive function, including the N-
back task (Minzenberg et al., 2009), with increases in other prefrontal cortex areas that may 
be compensatory in nature. As such, in schizophrenia, there may be a blunted activation 
state of the ACC with accompanying failure of glutamatergic modulation and impairments in 
task performance.  
It was interesting to note that across the 0-back condition the schizophrenia group showed 
a general increase in glutamatergic measures, while the healthy control group showed a 
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reduction, with a significant time by group crossover interaction for Glx/TCr. The 
schizophrenia group also had significantly lower accuracy and response times for this 
condition compared with the healthy control group. Taken together, these findings suggest 
during the 0-back condition, for what should be a period of relatively low executive load, 
the schizophrenia group found this condition cognitively challenging, with abnormal 
increases in glutamatergic measures. Furthermore, with increasing task difficulty they did 
not show the same dynamic modulation of glutamate levels as healthy volunteers.  
Static 1H-MRS studies of medial frontal lobe areas have reported increased glutamine (Stone 
et al., 2009)  and Glx (Tibbo et al., 2004) in individuals at high risk of psychosis together with 
increased glutamine in unmedicated patients with first episode psychosis (Theberge et al., 
2002; Theberge et al., 2007). In studies of chronic medicated patients however, studies have 
either found no difference (Reid et al., 2010; Wood et al., 2007) or reduced levels of Glx 
(Ohrmann et al., 2005; Rowland et al., 2013) and glutamate (Tayoshi et al., 2009; Theberge 
et al., 2003) compared with healthy controls, with one meta-analysis suggesting a 
progressive reduction with age in patients with schizophrenia (Marsman et al., 2013). It is 
conceivable that an excitotoxic effect may occur as a result from paradoxical increases in 
glutamatergic activity due to NMDAR hypofunction in the early stages of schizophrenia 
(Plitman et al., 2014). The longer-term result of this excitotoxicity would be a state of 
neurodegeneration with impaired glutamatergic modulation and is a potential explanation 
for the lack of any significant glutamatergic response between task conditions in the cohort 
of more chronic patients recruited in this study. 
To our knowledge, there are no other 1H-fMRS studies involving a BPII patient group to 
date. Only one 1H-fMRS study has been performed in a group of patients with a mood 
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disorder (MDD), where no significant increases in glutamate were detected during a Stroop 
Task (Taylor et al., 2015a) and is comparable with our finding of no significant glutamatergic 
response between the 0-back and 2-back conditions in a BPII group. Furthermore, in our 
study, depressive symptoms were negatively correlated with changes in Glu/TCr and Glx/TCr 
between the 0-back condition and 2-back condition (i.e. less depressed subjects had greater 
increases in glutamatergic concentrations). Together with alterations in glutamate 
metabolism, the role of inflammation in the pathophysiology in mood disorders is 
increasingly evident (Dantzer et al., 2008) and may provide explanation for the lack of a 
glutamatergic response in the BPII group in our study. One interesting hypothesis links the 
role of inflammation, glutamate and glia in mood disorders (Haroon et al., 2017). 
Inflammation can lead to increased release of glutamate into the extrasynaptic space by 
reducing the capacity of glial transporters to clear glutamate (McCullumsmith and Sanacora, 
2015). This glutamate excess can activate extrasynaptic NMDARs, resulting in atrophy of 
dendritic spines, loss of synaptic integrity and neuronal loss (Hardingham and Bading, 2010). 
Furthermore, this extrasynaptic glutamate can stimulate presynaptic metabotropic 
glutamate receptors (mGluR2/3) with reductions in synaptic glutamate transmission 
(Duman, 2014). 
The Glu/TCr and Glx/TCr responses observed in the healthy control group (12.6% and 14.7% 
respectively) are higher than those reported in other block-design 1H-fMRS studies using the 
N-back (Woodcock et al., 2018), Stroop Task (Taylor et al., 2015a; Taylor et al., 2015b) and 
other paradigms (Bednarik et al., 2015; Lin et al., 2012; Mangia et al., 2007; Schaller et al., 
2013; Schaller et al., 2014), where responses were in the range of 2-4%. The detected 
amplitude of changes in glutamatergic metabolites was more comparable with the range 
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reported in event-related 1H-fMRS studies (11-21.5%), where acquisition is time locked to 
stimulus onset (Apsvalka et al., 2015; Gussew et al., 2010; Lally et al., 2014). It is important 
to note for the initial planned comparison between total average 0-back and 2-back 
condition blocks there were no significant changes in glutamatergic metabolites in any 
groups. A potential explanation for this is that during prolonged stimulation habituation, 
adaptation and homeostatic effects might lead to difficulty detecting rapid glutamatergic 
dynamics (Giove et al., 2003; Mullins, 2018). A relatively rapid change in glutamate within 
the dLPFC during an N-back task has been reported with levels significantly higher by 2.7% 
during the first 32s and non-significantly higher during the final 32s of a 64s 2-back task 
block, compared with a resting condition. Our study mirrors this finding with the significant 
increases in glutamatergic metabolites occurring in the first 16s of 2-back condition 
compared with preceding last 16s of 0-back condition. This early increase may indicate 
novelty of task onset and a potential explanation for the larger glutamatergic responses 
seen in our study is that the higher temporal resolution allowed more of an early glutamate 
response function to be detected. 
An important issue to consider is what the changes detected by 1H-fMRS signify. Increases in 
glutamatergic metabolites, in the order of 2–5% over a period of minutes, can be explained 
by increased metabolic turnover, via a number of pathways including increased 
glutamate/glutamine cycling through the tricarboxylic acid cycle (TCA) (Rothman et al., 
2003), or increased flux through the malate-aspartate shuttle (MAS) (Mangia et al., 2007; 
McKenna et al., 2006). However, if increased glutamate/glutamine cycling would be causal 
for the increase in glutamate, the Glx level would not show such an increase due to a 
compensatory decrease in glutamine. It has been argued changes in the order of 12–18%, 
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especially when occurring over a matter of seconds, are too large to be explained by 
increased metabolic turnover alone (Jelen et al., 2018). One emerging theory is that of 
compartmental shifts which proposes that during neural activity glutamate is released from 
presynaptic vesicles (where metabolite movement is restricted, with a faster T2 relaxation 
rate) to more MRS visible synaptic, extracellular and astrocytic pools (where metabolite 
movement is less restricted and has a longer T2) (Mullins, 2018). This would imply 1H-fMRS is 
not detecting changes in overall glutamatergic concentrations in the specified brain volume, 
but rather compartmental shifts due to neural activity, as metabolites move from 
presynaptic vesicles to more visible synaptic, extracellular and astrocytic pools. Although 
speculative, the significant changes seen in the healthy control group in our study may 
represent a greater degree of variability and flexibility in glutamatergic neurotransmission, 
that is not seen in the schizophrenia or BPII groups. 
Limitations 
This study has a number of limitations. First, are the potential confounding effects of 
medication together with age and illness-stage of participants. Both antipsychotic and 
antidepressant medications are known to effect glutamatergic measures (de la Fuente-
Sandoval et al., 2013; Sanacora et al., 2012) and as a result could have altered baseline and 
glutamate responses in the N-back task. Likewise, age and illness-stage were not specifically 
controlled for in groups, both of which are factors that have been reported to effect 
glutamatergic measures (Marsman et al., 2013; Ohrmann et al., 2005; Stone et al., 2009; 
Theberge et al., 2003). However, post-hoc correlation analyses did not reveal any significant 
relationship with age and any changes in glutamatergic measures between the 0-back and 
2-back conditions in any of the separate or combined groups.  
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The acquired MRS signals were corrected for TCr but not for tissue type and T2 relaxation 
differences.  Although this would not affect the relative changes in the measured 
metabolites within individuals, tissue segmentation analysis revealed significantly lower 
grey matter proportion in the schizophrenia group compared with healthy controls and as 
such differences in groups could potentially be influenced by differences in grey matter 
volume. 
A further limitation was that the paradigm used in this study did not include a resting 
baseline condition. The number of errors seen in the schizophrenia group for the 0-back 
condition suggests this was challenging for some participants and glutamatergic measures 
may have already increased from a resting condition level, preventing changes between the 
0-back and 2-back conditions from being detected. Recent work has noted the importance 
of the ‘non-task-active’ behavioural paradigm in 1H-fMRS studies and suggests a continuous 
visual fixation cross exhibits less variability and lower levels of glutamate and therefore 
providing a better approximation of baseline state than other behavioural paradigms 
including eyes closed, flashing checkerboard or finger tapping (Lynn et al., 2018). An 
alternative explanation for the worse performance in the schizophrenia group that should 
also be considered is that of aberrant salience (Kapur, 2003), whereby these patients may 
be more likely to be inappropriately processing stimuli in their environment that would 
normally be considered irrelevant, and as a result might be less able/or willing to engage 
with and focus attention to the task in question.  
Finally, another significant limitation of this study is the field strength of 3T. Although 
spectral resolution is considered reasonably high at 3T, our 1H-fMRS technique was unable 
to reliably differentiate glutamate and glutamine. In addition, a number of spectra had to be 
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excluded due to CRMVB values >20%, for the Glu/TCr rmANOVA analysis in particular, with 
subsequent reduction in power. 
Conclusion 
This 1H-fMRS study has demonstrated significant dynamic changes in glutamatergic 
measures in the ACC during alternating conditions of the N-back task at 3T in a healthy 
control group but not in schizophrenia or BPII groups. The lack of any significant dynamic 
changes in the schizophrenia and BPII groups may reflect a dysfunction of glutamatergic 
neurotransmission. Future 1H-fMRS work at higher field strengths where both glutamate 
and glutamine can be reliably measured should investigate glutamatergic dynamics in 
schizophrenia and mood disorders, at various stages of illness progression in further detail. 
Such work might help in terms of stratifying patients to specific therapies, predicting 
functional outcome, or even be a potential aid in further developing novel treatment 
strategies that act to normalize impairments in glutamatergic neurotransmission in 
psychiatric disorders. 
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Table 1: Participant demographics 
 
 
 
 
 
 
 
 
 
 
 
Values shown are means ± standard deviations. Abbreviations: M/F, male/female; MADRS, Montgomery-
Asberg Depression Scale; YMRS, Young Mania Rating scale; SAPS, Scale for Assessment of Positive Symptoms; 
SANS, Scale for Assessment of Negative Symptoms. P- One-way ANOVA test (alpha=0.05, two tailed) or Chi-
squared for binary data, bold values indicate statistical significance.  
 
 
 
 
 
 
 
 
 
 
 
 
Group SCZ BPII HC P 
n 15 15 14  
Age  40.1 ± 10.0 38.6 ± 10.6 33.8 ± 10.5 0.248 
M/F 11/4 6/9 7/7 0.171 
MADRS 9.0 ± 8.6 9.20 ± 12.0 2.1 ± 2.6 0.059 
YMRS  3.5 ± 4.4 4.7 ± 3.6 1.3 ± 2.4 0.046 
SAPS 29.0 ± 23.5 3.8 ± 3.5 0.8 ± 1.8 <0.001 
SANS 13.8 ± 9.0 3.9 ± 3.9 0.1 ± 0.5 <0.001 
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Table 2. Pairwise comparisons for 0-back and 2-back conditions for mean Glu/TCr and Glx/TCr concentrations  
 0-b 2-b P 0-b3 2-b1 P 
HC 
[Glu/TCr] 0.90 ± 0.13 0.92 ± 0.11 0.630 0.86 ± 0.10 0.97 ± 0.07 0.004 
[Glx/TCr] 1.05 ± 0.15 1.08 ± 0.11 0.540 1.01 ± 0.10 1.16 ± 0.12 <0.001 
SCZ 
[Glu/TCr] 0.89 ± 0.14 0.89 ± 0.08 
  
0.964 0.98 ± 0.13 0.94 ± 0.06 0.346 
[Glx/TCr] 1.07 ± 0.17 1.09 ± 0.15 0.604 1.11 ± 0.22 1.14 ± 0.15 
 
0.467 
BPII 
[Glu/TCr] 0.91 ± 0.12 0.92 ± 0.11 0.854 0.88 ± 0.08 0.94 ± 0.15 0.295 
[Glx/TCr] 1.04 ± 0.14 1.06 ± 0.11 
 
0.527 
 
1.04 ± 0.11 1.11 ± 0.17 
 
0.246 
 
 
TOTAL 
[Glu/TCr] 0.90 ± 0.13 0.91 ± 0.10 0.667 0.90 ± 0.11 0.95 ± 0.10 0.073 
[Glx/TCr] 1.05 ± 0.15 1.08 ± 0.12 
 
0.292 
 
1.05 ± 0.15 1.14 ± 0.14 
 
0.004 
       
Values shown are means ± standard deviations.  Abbreviations: [Glu/TCr], The concentration of glutamate scaled to total creatine 
in IU (Institutional Units); [Glx/TCr], The concentration of Glx (glutamate + glutamine) scaled to total creatine in IU; HC, Healthy 
controls; SCZ, Schizophrenia; BPII, Bipolar disorder II; TOTAL, All groups combined; 0-b, 0-back total average; 2-b, 2-back total 
average; 0-b3, Averaged 3rd spectra of 0-back; 2-b1, Averaged 1st spectra of 2-back; P, P-value of paired t-test (alpha=0.05/4 
(Bonferroni corrected); two-tailed), bold values indicate statistical significance. 
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Table 3. Mean 1H-fMRS voxel tissue segmentation proportions 
 
 
 
 
 
 
 
 
 
 
  
 Group 
 HC SCZ BPII P 
CSF 0.189 ± 0.038 0.233 ± 0.067 0.232 ± 0.051 0.054 
GM 0.658 ± 0.035 0.596 ± 0.058 0.618 ± 0.052 0.008 
WM 0.153 ± 0.033 0.171 ± 0.024 0.152 ± 0.017 0.083 
Values shown are mean proportions ± standard deviations. Abbreviations:  CSF, 
cerebrospinal fluid; GM, grey matter; WM, white matter; P, P-value of One-way 
ANOVA test (alpha=0.05, two tailed), bold values indicate statistical significance. 
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Table 4. Mean accuracy and response times of each group for 0-back and 2-back conditions 
 
 
 Accuracy (% ± SD) Response time (ms ± SD) 
 0-back 2-back Difference P 0-back 2-back Difference P 
HC 94.0 ± 3.2 86.5 ± 8.5 -7.5 ± 6.9 <0.001 633 ± 99 766 ± 105 133 ± 107 <0.001 
SCZ 84.7 ± 12.7 68.1 ± 18.5 -16.6 ± 11.0 <0.001 800 ± 221 945 ± 269 145 ± 143 0.002 
BPII 95.2 ± 1.9 84.6 ± 11.7 -10.6 ± 10.4 <0.001 632 ± 68 789 ± 153 157 ± 114 <0.001 
Accuracy measured in terms of mean percentage of correct responses (%) ± standard deviation (SD). Response time is mean response 
time in milliseconds (ms) ± standard deviation (SD). P-values, paired t-tests for difference in accuracy and response times between 0-
back and 2-back conditions (alpha=0.05); two-tailed), bold values indicate statistical significance. 
   Table 5. Correlations with metabolite level changes between total averaged 0-back and 2-back condition  
 
 
Age 
 
P D- Acc P D-RT 
 
P 
 
MADRS 
 
P 
 
YMRS 
 
P 
 
SAPS 
 
P 
 
SANS 
 
P 
HC 
D[Glu/TCr] -0.091 0.758 0.025 0.933 0.275 0.341 0.150 0.609 0.265 0.360 0.253 0.383 0.242 0.404 
D [Glx/TCr] -0.083 0.779 0.029 0.921 0.325 0.256 0.251 0.387 0.261 0.368 0.302 0.295 0.252 0.385 
SCZ 
D [Glu/TCr] 0.210 
 
0.490 -0.513 
 
0.073 0.326 0.276 -0.415 0.159 0.076 0.805 -0.474 0.102 0.054 0.862 
D [Glx/TCr] 0.316 0.271 -0.565 0.035 0.463 
 
0.096 -0.317 0.270 0.076 0.797 -0.202 0.488 0.015 0.961 
BPII 
D [Glu/TCr] 0.138 0.637 -0.201 0.490 0.267 0.357 -0.274 0.343 -0.202 0.489 -0.117 0.690 -0.132 0.652 
D [Glx/TCr] 0.115 
 
0.683 -0.208 
 
0.458 0.279 
 
0.315 -0.109 0.698 -0.202 0.470 0.000 0.999 0.004 0.989 
 
 
TOTAL 
D [Glu/TCr] 0.043 0.789 -0.174 0.276 0.267 0.091 -0.226 0.155 -0.006 0.971 -0.172 0.283 -0.053 0.743 
D [Glx/TCr] 0.076 
 
0.626 -0.207 
 
0.183 0.339 
 
0.026 -0.108 0.491 0.019 0.903 -0.079 0.615 -0.014 0.927 
               
 
All correlation coefficients shown are Pearson r with accompanying P value (alpha=0.05; two-tailed). Abbreviations: D [Glu/TCr] Change in average 
glutamate level, scaled to total creatine, between 0-back and 2-back condition ; D [Glx/TCr], Change in average glutamine concentration, scaled to total 
creatine, between 0-back and 2-back condition; D- Acc, change in accuracy between 0-back and 2-back; D-RT change in response time between 0-back 
and 2-back condition; MADRS, Montgomery-Asberg Depression Scale; YMRS, Young Mania Rating scale; SAPS, Scale for Assessment of Positive 
Symptoms; SANS, Scale for Assessment of Negative Symptoms  HC, Healthy controls; SCZ, Schizophrenia; BPII, Bipolar disorder II; TOTAL, All groups 
combined. 
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Table 6. Correlations with metabolite level changes from averaged final spectra of 0-back condition and averaged first spectra of 
2-back condition.   
 
 
Age 
 
P D- Acc P D-RT 
 
P 
 
MADRS 
 
P 
 
YMRS 
 
P 
 
SAPS 
 
P 
 
SANS 
 
P 
HC 
D[Glu/TCr] 0.291 0.386 0.027 0.936 -0.606 0.048 -0.116 0.734 -0.142 0.677 0.006 0.987 -0.324 0.331 
D [Glx/TCr] 0.073 0.811 0.101 0.744 -0.336 0.262 0.268 0.377 0.013 0.966 0.213 0.484 -0.125 0.683 
SCZ 
D [Glu/TCr] -0.703 
 
0.052 -0.358 
 
0.384 0.178 0.673 -0.607 0.111 0.323 0.435 -0.591 0.123 -0.190 0.652 
D [Glx/TCr] -0.063 0.837 -0.129 0.674 0.078 
 
0.800 -0.523 0.067 0.240 0.431 -0.309 0.304 0.015 0.962 
BPII 
D [Glu/TCr] -0.303 0.395 0.684 0.029 -0.432 0.212 -0.639 0.047 0.273 0.445 0.145 0.690 -0.016 0.965 
D [Glx/TCr] -0.460 
 
0.114 0.207 
 
0.498 -0.497 
 
0.084 -0.585 0.036 -0.189 0.536 0.302 0.315 0.332 0.268 
 
 
TOTAL 
D [Glu/TCr] -0.186 0.334 0.252 0.187 -0.219 0.254 -0.632 <0.001 0.098 0.615 -0.492 0.007 -0.407 0.028 
D [Glx/TCr] -0.229 
 
0.161 0.133 
 
0.420 -0.203 
 
0.215 -0.532 <0.001 -0.071 0.669 -0.244 0.134 -0.128 0.438 
               
 
All correlation coefficients shown are Pearson r with accompanying P value (alpha=0.05; two-tailed). Abbreviations: D [Glu/TCr] Change in average 
glutamate level, scaled to total creatine, between averaged 3rd spectra of 0-back and averaged 1st Spectra of 2-back; D [Glx/TCr], Change in average 
glutamine concentration, scaled to total creatine, between averaged 3rd spectra of 0-back and averaged 1st Spectra of 2-back; D- Acc, change in accuracy 
between 0-back and 2-back; D-RT change in response time between 0-back and 2-back condition; MADRS, Montgomery-Asberg Depression Scale; YMRS, 
Young Mania Rating scale; SAPS, Scale for Assessment of Positive Symptoms; SANS, Scale for Assessment of Negative Symptoms  HC, Healthy controls; SCZ, 
Schizophrenia; BPII, Bipolar disorder II; TOTAL, All groups combined. 
  
 
 
 Figure 1. N-back task paradigm depiction.  
 
The alternating N-back conditions each lasted 48s each, with 18 blocks in total (0-b; 0-back; 1-b; 1back, 2-b; 2-
back; 3-b; 3-back). During each 48s block three spectra were acquired (One every 16s, NEX=8). Instructions 
were presented at the beginning of each block for 3000ms, 18 sequential letters were presented for 1000ms 
with 1500ms between subsequent letters and participants were allowed 1900ms to record their response.  
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Figure 2. 1H-fMRS voxel placement. 
Sagittal cross-section depicting 1H-fMRS voxel placement, located in the bilateral ACC.  
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Figure 3. Averaged time courses of Glx/TCr level estimates according to participant group 
 
(a) Healthy controls (b) schizophrenia (c) bipolar disorder II and (d) all groups combined. Unshaded area 
indicates 0-back and shaded area indicates 2-back task condition. Each time point represents 16s period 
average. 0-b1, averaged 1st spectra of 0-back; 0-b2, averaged 2nd spectra of 0-back; 0-b3, averaged 3rd spectra 
of 0-back; 2-b1, averaged 1st spectra of 2-back; 2-b2, averaged 2nd spectra of 2-back; 2-b3, averaged 3rd spectra 
of 2-back. IU, Institutional Units. Error bars represent standard error of the mean. 
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Figure 4. Averaged levels of Glx/TCr across 0-back condition for schizophrenia and healthy 
control groups 
 
Glx/TCr in Institutional Units (IU) for healthy control (continuous line) and schizophrenia groups (broken line) 
across the 0-back condition. 0-b1, averaged 1st spectra of 0-back; 0-b3, averaged 3rd spectra of 0-back. Error 
bars represent standard error of the mean. 
 
 
 
 
